Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 565

Sort by

Sort Order Select

Journal Articles

Association between ABO haplotypes and the risk of venous thrombosis: impact on disease risk estimation

Blood (2021) 137 (17): 2394–2402.

https://doi.org/10.1182/blood.2020008997

Published: 2021

Includes: Supplemental data

Journal Articles

Cardiovascular adverse events of ibrutinib

Inhye E. Ahn

Blood (2019) 134 (22): 1881–1882.

https://doi.org/10.1182/blood.2019002805

Published: 2019

Journal Articles

Patient-Specific Risk Factors Independently Influence Survival in Myelodysplastic Syndromes in an Unbiased Review of EHR Records

Travis Spaulding, MD, Nicholas Strayer, Andrew Sochacki, MD, Shannon Stockton, MD, Alexander Silver, Rodney Dixon Dorand, MD PhD, Siwei Zhang, PhD, Ya-Chen Lin, Yaomin Xu, PhD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 5440.

https://doi.org/10.1182/blood-2019-122400

Published: 2019

Journal Articles

Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Effect of a One-Year Consolidation Treatment with Ponatinib 15 Mg on Treatment Free-Remission Rate in Patients with Philadelphia-Positive Chronic Myeloid Leukemia, Who Had Previously Achieved a Deep Molecular Response with Imatinib (PonaZero_study)

Valentin Garcia Gutierrez, MD PhD, Luis Felipe Casado, Rosa Ayala, MD PhD, Fermin Sanchez-Guijo, MD PhD, Juan Carlos Hernandez Boluda, María Teresa Gomez Casares, Blanca Xicoy, MD MSc, Begonya Maestro, PhD, Juan Luis Steegmann, Arturo Garcia de Diego

Blood (2019) 134 (Supplement_1): 5904.

https://doi.org/10.1182/blood-2019-125627

Published: 2019

Journal Articles

Ponatinib Treatment in CML and Ph+ ALL Patients: Real-Life Data from the Czech Registries

Eva Koriťáková, RNDr., PhD, Michael Doubek, MD PhD, Edgar Faber, MD PhD, Daniela Žáčková, MD PhD, Jan M. Horáček, MD PhD, Petra Bělohlávková, MD PhD, Eduard Cmunt, MD PhD, František Folber, MD PhD, Pavel Jindra, MD PhD, Hana Klamová, MD PhD, Zdeněk Kořístek, MD PhD, Lukáš Stejskal, MD, Tomáš Szotkowski, MD PhD, Cyril Šálek, MD PhD, Renata Kellnerová, MD PhD, Marika Chrápavá, Mgr.

Blood (2019) 134 (Supplement_1): 5905.

https://doi.org/10.1182/blood-2019-126395

Published: 2019

Journal Articles

Rationale and Design of a Phase 3 Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Rodney H Falk, MD, Morie A Gertz, MD, Merrill D Benson, MD, Gustavo Buchele, MD PhD, Michela Brambatti, MD MS, Sotirios Tsimikas, MD, Nicholas J Viney, Bsc, Li-Jung Tai, MD PhD, Cecilia Monteiro, MD PhD, Qingqing Yang, MS, Louis St L O'Dea, MB B.Ch. BAO, FRCP, Ewa Karwatowska-Prokopczuk, MD PhD, Eugene Schneider, MD, Richard S Geary, PhD, Brett P Monia, PhD

Blood (2019) 134 (Supplement_1): 5764.

https://doi.org/10.1182/blood-2019-129269

Published: 2019

Journal Articles

Interim Results of the Real-Life Study Evaluating the Efficacy and Safety of Ponatinib "Topase" Reveals Induction of Early Molecular Responses in Patients with TKI-Resistant or Intolerant CML

Agnès Guerci, MD PhD, Emilie Cayssials, MD, Philippe Rousselot, MD PhD, Francoise Huguet, MD, Valerie Coiteux, MD, Marc G. Berger, MD PhD, Gabriel Etienne, MD PhD, Ali G Turhan, MD PhD

Blood (2019) 134 (Supplement_1): 5908.

https://doi.org/10.1182/blood-2019-122769

Published: 2019

Journal Articles

Low-Dose BRAF-Inhibitors in the Treatment of Histiocytic Disorders with the BRAF-V600E Mutation

Gordon Ruan, MD, Gaurav Goyal, MBBS, Jithma P. Abeykoon, MD, N. Nora Bennani, MD, Karen Rech, MD, Jason Young, MD, Mithun Vinod Shah, MD PhD, Ronald S. Go, MD

Blood (2019) 134 (Supplement_1): 5895.

https://doi.org/10.1182/blood-2019-124891

Published: 2019

Journal Articles

Population-Based, Cause-Specific Risk of Non-Lymphoma Deaths Among 20,491 Adults with Classical Hodgkin Lymphoma (cHL) Treated with Initial Chemotherapy in the United States, 2000-2015

Graca M. Dores, MD, Rochelle E. Curtis, MA, Nicole H. Dalal, BA, Martha S. Linet, MD MPH, Lindsay M. Morton, PhD

Blood (2019) 134 (Supplement_1): 4034.

https://doi.org/10.1182/blood-2019-124831

Published: 2019

Journal Articles

Metabolomics Profile of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors

Giovanni Caocci, MD, Martino Deidda, Antonio Noto, Christian Cadeddu, Marianna Greco, Maria Pina Simula, Olga Mulas, Daniele Cocco, Claudia Fattuoni, Giuseppe Mercuro, Giorgio La Nasa

Blood (2019) 134 (Supplement_1): 4144.

https://doi.org/10.1182/blood-2019-124323

Published: 2019

Journal Articles

Cardiovascular (CV)-Related Hospitalizations and Associated Costs Among US Patients in Simplicity: An Observational Study of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in Routine Clinical Practice

Stuart L. Goldberg, MD, Michael J. Mauro, MD, Jorge E. Cortes, MD, Scott Justin Keating, MSc, BSc, Hitesh Bhandari, Clara Chen, PhD BS, MS

Blood (2019) 134 (Supplement_1): 4151.

https://doi.org/10.1182/blood-2019-128290

Published: 2019

Journal Articles

Trends in Early Mortality from Multiple Myeloma (MM): A Population-Based Analysis

Vivek Kumar, MD, M.B.,B.S., Mays F Abdulazeez, BMSC, Suman Biswas, MD, Sri Lekha Bodepudi, Vivek Roy, MD, Taimur Sher, MD, Meghna Ailawadhi, MD, Victoria R. Alegria, Aneel Paulus, MD, Salman Ahmed, MD, Prachi Jani, MD, Asher A. Chanan-Khan, MD, Sikander Ailawadhi, MD

Blood (2019) 134 (Supplement_1): 71.

https://doi.org/10.1182/blood-2019-124799

Published: 2019

Journal Articles

Toxicities and Outcomes of Acalabrutinib-Treated Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients

Blood (2019) 134 (Supplement_1): 4311.

https://doi.org/10.1182/blood-2019-130062

Published: 2019

Journal Articles

High Serum VEGF Level in Erdheim-Chester Disease: Correlation with Cardiovascular Involvement and Response to Treatment

Anaïs Roeser, MD, Marine Bravetti, MD, Levi-Dan Azoulay, MD, Makoto Miyara, MD, Jean-François Emile, MD, Jean Donadieu, MD PhD, Zahir Amoura, MD MSc, Fleur Cohen-Aubart, MD PhD, Julien Haroche

Blood (2019) 134 (Supplement_1): 2324.

https://doi.org/10.1182/blood-2019-129984

Published: 2019

Journal Articles

AML-CM Score Predicts Prognosis in Hemato-Geriatric Patients with New-Onset Acute Myeloid Leukemia (AML) Who Receive Hypomethylating Agents (HMA)

Giovanni Marconi, Roberta di Nicola, Chiara Sartor, MD, Mariachiara Abbenante, MD, Jacopo Nanni, MD, Gianluca Cristiano, MD, Sarah Parisi, MD PhD, Carmen Baldazzi, PhD, Maria Chiara Fontana, PhD, Lorenza Bandini, Emanuela Ottaviani, Nicoletta Testoni, Giovanni Martinelli, MD, Michele Baccarani, MD, Cristina Papayannidis, Stefania Paolini, MD PhD, Michele Cavo, Antonio Curti, MD PhD

Blood (2019) 134 (Supplement_1): 2617.

https://doi.org/10.1182/blood-2019-130630

Published: 2019

Journal Articles

Preliminary Results of CML1214, a Survey on Ponatinib Compassionate Use in Italy By the Gimema CML Working Party

Blood (2019) 134 (Supplement_1): 2931.

https://doi.org/10.1182/blood-2019-125052

Published: 2019

Journal Articles

Cytogenetic and Molecular Response with First- and Second-Generation Tyrosine Kinase Inhibitor (TKI) Therapy in Simplicity: An Observational Study of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

Jorge E. Cortes, MD, Clara Chen, PhD BS, MS, Catherine Davis, PharmD, Stuart L. Goldberg, MD, Michael J. Mauro, MD

Blood (2019) 134 (Supplement_1): 2929.

https://doi.org/10.1182/blood-2019-127959

Published: 2019

Journal Articles

The Impact of Comorbidity on Quality of Life in Chronic Myeloid Leukemia Patients with Deep Molecular Response Who Stopped Therapy By Tyrosine Kinase Inhibitors: Results of the RU-SKI Trial

Tatyana Ionova, PhD Professor, Tatiana Nikitina, PhD, Natalia Porfirieva, Anna Petrova, MD, Ekaterina Yu. Chelysheva, MD PhD, Oleg A. Shukhov, MD PhD, Anastasiya Bykova, MD, Galina Gusarova, MD PhD, Irina Nemchenko, MD PhD, Nikolay Tsyba, MD PhD, Anna G. Turkina, Prof., MD

Blood (2019) 134 (Supplement_1): 2925.

https://doi.org/10.1182/blood-2019-122041

Published: 2019

Journal Articles

Stroke Risk in Blood or Marrow Transplant (BMT) Survivors - a Report from the BMT Survivor Study (BMTSS)

Radhika Gangaraju, MD, Yanjun Chen, MS, Lindsey Hageman, MPH, Jessica Wu, MPH, Wendy Landier, PhD CRNP, Liton F. Francisco, BS, Andrew McDonald, Donna Murdaugh, PhD, Michelle Kung, MA, Emily Ness, MPH, Daniel J. Weisdorf, MD, Stephen J Forman, MD, Lennie Wong, PhD, Mukta Arora, MD, Saro H. Armenian, DO, MPH, Smita Bhatia, MDMPH

Blood (2019) 134 (Supplement_1): 3298.

https://doi.org/10.1182/blood-2019-124564

Published: 2019

Journal Articles

Economic Burden of End Organ Damage Among Patients with Sickle Cell Disease in the US

Xue Song, Andrew D. Campbell, MD, Ze Cong, PhD, Irene Agodoa, MD, Diane Martinez, DrPH, MPH, Carolyn R. Lew, PhD, Danae Black, Helen Varker, Chris Chan, Sophie M. Lanzkron, MD

Blood (2019) 134 (Supplement_1): 3388.

https://doi.org/10.1182/blood-2019-127173

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Association between ABO haplotypes and the risk of venous thrombosis: impact on disease risk estimation

Cardiovascular adverse events of ibrutinib

Patient-Specific Risk Factors Independently Influence Survival in Myelodysplastic Syndromes in an Unbiased Review of EHR Records

Ponatinib Treatment in CML and Ph+ ALL Patients: Real-Life Data from the Czech Registries

Rationale and Design of a Phase 3 Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Interim Results of the Real-Life Study Evaluating the Efficacy and Safety of Ponatinib "Topase" Reveals Induction of Early Molecular Responses in Patients with TKI-Resistant or Intolerant CML

Low-Dose BRAF-Inhibitors in the Treatment of Histiocytic Disorders with the BRAF-V600E Mutation

Population-Based, Cause-Specific Risk of Non-Lymphoma Deaths Among 20,491 Adults with Classical Hodgkin Lymphoma (cHL) Treated with Initial Chemotherapy in the United States, 2000-2015

Metabolomics Profile of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors

Cardiovascular (CV)-Related Hospitalizations and Associated Costs Among US Patients in Simplicity: An Observational Study of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in Routine Clinical Practice

Trends in Early Mortality from Multiple Myeloma (MM): A Population-Based Analysis

Toxicities and Outcomes of Acalabrutinib-Treated Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients

High Serum VEGF Level in Erdheim-Chester Disease: Correlation with Cardiovascular Involvement and Response to Treatment

AML-CM Score Predicts Prognosis in Hemato-Geriatric Patients with New-Onset Acute Myeloid Leukemia (AML) Who Receive Hypomethylating Agents (HMA)

Preliminary Results of CML1214, a Survey on Ponatinib Compassionate Use in Italy By the Gimema CML Working Party

Cytogenetic and Molecular Response with First- and Second-Generation Tyrosine Kinase Inhibitor (TKI) Therapy in Simplicity: An Observational Study of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

The Impact of Comorbidity on Quality of Life in Chronic Myeloid Leukemia Patients with Deep Molecular Response Who Stopped Therapy By Tyrosine Kinase Inhibitors: Results of the RU-SKI Trial

Stroke Risk in Blood or Marrow Transplant (BMT) Survivors - a Report from the BMT Survivor Study (BMTSS)

Economic Burden of End Organ Damage Among Patients with Sickle Cell Disease in the US

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only